3017.TW (3017.TW)

$874.6B
Market Cap
46.2
P/E Ratio
0.47
Beta
0.49%
Dividend Yield
Piotroski 6/9Altman Z 6.8 SafeROIC−WACC +29.1%

Quantitative Summary

Deterministic

Financial health is average: Piotroski 6/9, Altman Z 6.8.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation efficiency demonstrates exceptional quality, with a return on invested capital of 37.1% significantly outpacing the weighted average cost of capital at 8.0%, yielding an expansive spread of +29.1%. This high ROIC is underpinned by robust profitability metrics, including a net margin of 13.7% and gross margin of 25.8%, while the Piotroski F-Score of 6/9 indicates strong fundamental stability relative to peers. The Altman Z-Score of 6.8 further suggests a low probability of financial distress, reinforcing the durability of the earnings base despite the aggressive revenue expansion observed in recent periods.

Valuation metrics present a dichotomy between historical performance and intrinsic value estimates. A current price-to-earnings ratio of 46.2x implies that market participants are pricing in substantial future growth expectations, though this premium must be weighed against sector averages which were not provided for direct comparison. In contrast, the discounted cash flow model suggests a fair value of $4,283, indicating whether the current trading price aligns with or deviates from these calculated intrinsic levels depends on the specific market entry point relative to this benchmark. The divergence between the high multiple and the DCF floor highlights the sensitivity of valuation to growth assumption changes inherent in such a rapidly expanding revenue profile of 94.6% year-over-year.

No additional risk factor deltas, insider activity data, or Fama-French alpha statistics were supplied for this analysis; consequently, the risk-reward assessment relies entirely on the provided fundamental and valuation metrics. While the high growth rate and superior capital returns suggest a compelling investment thesis based on historical performance, the elevated multiple leaves little margin of safety if future revenue expansion decelerates from its current trajectory or if market sentiment shifts regarding sector valuations. Investors must carefully evaluate whether the implied growth embedded in the 46.2x P/E ratio is sustainable given the company's specific operational constraints and macroeconomic headwinds not captured in the supplied dataset.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →6%8%10%
2%$5546$3667$2714
3%$7184$4283$3020
4%$10460$5210$3428

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=8.0%, terminal growth 3%. Fair value $4283 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

6/9
Piotroski F-Score
Average — mixed operational signals
6.8
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.

Profitability & Value Creation

25.8%
Gross Margin
13.7%
Net Margin
37.1%
ROIC
8.0%
WACC
ROIC − WACC Spread: +29.1%— Positive value creation spread.
+94.6%
Revenue Growth (YoY)
+134.8%
Earnings Growth (YoY)
31.8B
Free Cash Flow
12%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

Balance Sheet Health

2.17x
Debt / Equity
1.29x
Current Ratio
48.5x
Interest Coverage
-1.6x
Net Debt / EBITDA
3.86%
FCF Yield
32.6B
EBITDA

Earnings Surprise History

Q4
✓ Beat
Est: $7.11
Act: $8.28
+16.4%
Q3
✓ Beat
Est: $9.96
Act: $10.30
+3.5%
Q2
✓ Beat
Est: $13.39
Act: $13.46
+0.5%
Q1
✗ Miss
Est: $17.32
Act: $16.70
-3.6%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

19.2
Forward P/E
PEG Ratio
19.54
Price/Book
6M
Avg Volume
$2310.00
52W High
$340.50
52W Low
52W Range Position

ETF Contagion Visualizer

Simulate a price drop in 3017.TW to visualize passive redemption contagion across ETFs and collateral stocks.

3017.TW Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
3017.TWEpicenterEWTETF2330.TWLow Risk2308.TWLow Risk2454.TWLow Risk2317.TWMed Risk2383.TWLow Risk
3017.TW Price Drop (%)0

If 3017.TW (3017.TW) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Taiwan Semiconductor Manufacturing Co Ltd (2330.TW) as the most exposed collateral stock, sharing 1 ETFs with 3017.TW. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 1 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

3017.TW Ownership Dynamics

Ticker
3017.TW

ETFs with Highest 3017.TW Exposure

Float lock-up computed from 0 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

3017.TW Capital Efficiency

How efficiently does 3017.TW convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$31.8B
EBITDA
$32.6B
FCF Conversion
97%
Reinvestment Rate
3%
97% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
37.1%
ROIC − WACC Spread
29.1%

3017.TW converts 97% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 29.1% confirms that reinvested capital creates shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Compare 3017.TW to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.